» Articles » PMID: 32938720

Structure of Cytochrome P450 2C9*2 in Complex with Losartan: Insights into the Effect of Genetic Polymorphism

Overview
Journal Mol Pharmacol
Date 2020 Sep 17
PMID 32938720
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The human CYP2C9 plays a crucial role in the metabolic clearance of a wide range of clinical therapeutics. The *2 allele is a prevalent genetic variation in CYP2C9 that is found in various populations. A marked reduction of catalytic activity toward many important drug substrates has been demonstrated by CYP2C9*2, which represents an amino acid variation at position 144 from arginine to cysteine. The crystal structure of CYP2C9*2 in complex with an antihypertensive drug losartan was solved using X-ray crystallography at 3.1-Å resolution. The Arg144Cys variation in the *2 complex disrupts the hydrogen-bonding interactions that were observed between the side chain of arginine and neighboring residues in the losartan complex of CYP2C9 and the wild-type (WT) ligand-free structure. The conformation of several secondary structural elements is affected, thereby altering the binding and orientation of drug and important amino acid side chains in the distal active site cavity. The new structure revealed distinct interactions of losartan in the compact active site of CYP2C9*2 and differed in occupancy at the other binding sites previously identified in the WT-losartan complex. Furthermore, the binding studies in solution using losartan illustrated lower activity of the CYP2C9*2 compared with the WT. Together, the findings yield valuable insights into the decreased hydroxylation activity of losartan in patients carrying CYP2C9*2 allele and provide a useful framework to investigate the effect of a single-nucleotide polymorphism that leads to altered metabolism of diverse drug substrates. SIGNIFICANCE STATEMENT: The *2 allele of the human drug-metabolizing enzyme CYP2C9 is found in different populations and results in significantly reduced activity toward various drug substrates. How the CYP2C9*2 variant induces altered drug metabolism is poorly understood given that the Arg144Cys variation is located far away from the active site. This work yield insight into the effect of distal variation using multitude of techniques that include X-ray crystallography, isothermal titration calorimetry, enzymatic characterization, and computational studies.

Citing Articles

Structural and biophysical analysis of cytochrome P450 2C9*14 and *27 variants in complex with losartan.

Parikh S, Edara S, Deodhar S, Singh A, Maekawa K, Zhang Q J Inorg Biochem. 2024; 258:112622.

PMID: 38852293 PMC: 11285081. DOI: 10.1016/j.jinorgbio.2024.112622.


Multilevel superposition for deciphering the conformational variability of protein ensembles.

Amisaki T Brief Bioinform. 2024; 25(3).

PMID: 38557679 PMC: 10983786. DOI: 10.1093/bib/bbae137.


Inhibitory mechanism of vortioxetine on CYP450 enzymes in human and rat liver microsomes.

Zhan Y, Wang A, Yu Y, Chen J, Xu X, Nie J Front Pharmacol. 2023; 14:1199548.

PMID: 37790811 PMC: 10544575. DOI: 10.3389/fphar.2023.1199548.


Silencing of Contributes to Mortality of .

Chen D, Yan R, Xu Z, Qian J, Yu Y, Zhu S Insects. 2022; 13(11).

PMID: 36421975 PMC: 9696999. DOI: 10.3390/insects13111072.


Four Decades of Cytochrome P450 2B Research: From Protein Adducts to Protein Structures and Beyond.

Roberts A, Stevens J, Szklarz G, Scott E, Kumar S, Shah M Drug Metab Dispos. 2022; 51(1):111-122.

PMID: 36310033 PMC: 11022898. DOI: 10.1124/dmd.122.001109.


References
1.
Ghanayem B, Bell D, Zhang Z, Kaminsky L, Shenfield G, Miners J . The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 1996; 6(4):341-9. DOI: 10.1097/00008571-199608000-00007. View

2.
Cuff A, Martin A . Analysis of void volumes in proteins and application to stability of the p53 tumour suppressor protein. J Mol Biol. 2004; 344(5):1199-209. DOI: 10.1016/j.jmb.2004.10.015. View

3.
Chen V, Arendall 3rd W, Headd J, Keedy D, Immormino R, Kapral G . MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr. 2010; 66(Pt 1):12-21. PMC: 2803126. DOI: 10.1107/S0907444909042073. View

4.
Williams P, Cosme J, Ward A, Angove H, Vinkovic D, Jhoti H . Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature. 2003; 424(6947):464-8. DOI: 10.1038/nature01862. View

5.
Goldstein J . Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001; 52(4):349-55. PMC: 2014584. DOI: 10.1046/j.0306-5251.2001.01499.x. View